DTB: Vol 31 No 4
Glucagon-like peptide 1 receptor agonists (GLP1a) and the problem of obesity
Bol Inf Farmacoter Navar. 2023;31 (4):1-19
https://doi.org/10.54095/BITN20233104EN
The role of GLP1a in therapeutic medicine remains to be clearly defined, therefore the prescription thereof should be restricted to the sub-groups that will achieve the greatest benefit. Accessibility to lifestyle interventions should be ensured. The solution to the obesity epidemic requires political intervention regarding the social factors that promote it.
Authors:
SANTI ARANA BALLESTAR
Family and Community Medicine resident.
Centro de Salud Parque Goya (Zaragoza).
CRUZ BARTOLOMÉ MORENO
Family and Community Medicine Specialist.
Centro de Salud Parque Goya (Zaragoza).
Family and Community Care Teaching Unit. Sector Zaragoza I.
